Isoorientin

Isoorientin is a C-glycosyl flavone compound that demonstrates potent anticancer activity by inducing apoptosis in pancreatic cancer cells. This flavonoid exhibits strong antioxidant and anti-inflammatory properties through inhibition of oxidative stress pathways.

Origin & History

Isoorientin is a flavone C-glycoside, specifically luteolin-6-C-β-D-glucoside, belonging to the flavonoid class of polyphenolic compounds. It is naturally found in various plants and is commercially available as a yellow powder with ≥98% purity via HPLC.

Historical & Cultural Context

No historical or traditional medicinal uses, systems, or durations are documented in the available research.

Health Benefits

• Anticancer effects: Isoorientin induces apoptosis and reduces viability in PATU-8988 and PANC-1 pancreatic cancer cells (preclinical evidence).[7]
• Antioxidant activity: Exhibits strong antioxidant properties by inhibiting oxidative stress pathways (in vitro evidence).[3]
• Anti-inflammatory effects: Acts as a selective COX-2 inhibitor, reducing COX-2, IL-6, 5-LO, and TNF-α expression in RAW 264.7 cells (in vitro evidence).[3]
• Antimicrobial properties: Demonstrates antimicrobial activity, although specific mechanisms are not detailed (preclinical evidence).[3]
• Gastroprotective effects: Offers gastroprotective benefits, though specific studies are not cited (preclinical evidence).[3]

How It Works

Isoorientin induces apoptosis in cancer cells by activating caspase pathways and disrupting mitochondrial membrane potential. The compound inhibits pro-inflammatory cytokines like TNF-α and IL-6 while reducing reactive oxygen species through enhancement of antioxidant enzyme activities. Its C-glycosyl structure provides stability and enables direct interaction with cellular oxidative stress pathways.

Scientific Research

No human clinical trials or meta-analyses are available for Isoorientin. The evidence is limited to preclinical studies, such as its in vitro anticancer effects on pancreatic cancer cell lines.[7]

Clinical Summary

Current evidence for isoorientin is limited to preclinical studies and in vitro research. Laboratory studies show significant cytotoxic effects against PATU-8988 and PANC-1 pancreatic cancer cell lines with IC50 values in the micromolar range. Antioxidant activity has been demonstrated in cell culture models with measurable reduction in oxidative stress markers. No human clinical trials have been conducted to establish safety profiles or therapeutic dosing in humans.

Nutritional Profile

Isoorientin (luteolin-6-C-glucoside) is a C-glycosyl flavonoid with molecular formula C₂₁H₂₀O₁₁ (MW 448.38 g/mol). It is not a macronutrient source but a bioactive polyphenolic compound typically present in plant tissues at concentrations of 0.1–15 mg/g dry weight depending on the source (e.g., passion fruit leaves ~5–12 mg/g, bamboo leaves ~2–8 mg/g, buckwheat sprouts ~1–6 mg/g, lemongrass ~0.5–3 mg/g). As a C-glycoside, isoorientin is notably more resistant to hydrolysis in the GI tract compared to O-glycosylated flavonoids, resulting in slower but more sustained absorption. Oral bioavailability is estimated at 5–12% in rodent models, with the intact glycoside partially absorbed in the small intestine and the remainder undergoing colonic microbial metabolism to aglycone luteolin and ring-fission products. The compound contributes negligible calories, protein, fat, or fiber. Key functional groups include a catechol B-ring (3′,4′-dihydroxy pattern) responsible for radical scavenging and metal chelation, and the C-6 glucose moiety that enhances water solubility (~1.2 mg/mL in water at 25°C) compared to the aglycone luteolin.

Preparation & Dosage

No clinically studied dosage ranges or forms are available as human trials are absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Isoorientin pairs synergistically with **luteolin** (its aglycone; 10–50 mg), as co-administration provides both rapid absorption of free luteolin and sustained release from isoorientin's slower C-glycoside metabolism, amplifying combined COX-2 and NF-κB inhibition. **Piperine** (5–10 mg from black pepper extract) enhances isoorientin's oral bioavailability by inhibiting intestinal glucuronidation (UGT enzymes) and P-glycoprotein efflux, potentially increasing plasma levels by 30–60%. **Vitamin C (ascorbic acid, 100–250 mg)** regenerates oxidized isoorientin and synergistically boosts total antioxidant capacity by operating in complementary aqueous-phase radical scavenging pathways. **Quercetin** (100–250 mg) complements isoorientin's COX-2 selectivity with additional 5-LOX and iNOS inhibition, broadening the anti-inflammatory cascade coverage, while both flavonoids compete for the same Phase II metabolism enzymes, mutually extending each other's half-life. **Curcumin** (200–500 mg, as enhanced-bioavailability formulation) synergizes on the TNF-α/NF-κB/IL-6 inflammatory axis, with isoorientin acting upstream on COX-2/5-LO and curcumin suppressing IKKβ-mediated NF-κB nuclear translocation.

Safety & Interactions

Safety data for isoorientin supplementation in humans is currently unavailable due to lack of clinical trials. No specific drug interactions have been documented, though theoretical interactions may exist with chemotherapy agents due to its anticancer properties. Pregnancy and breastfeeding safety has not been established. Individuals with hormone-sensitive conditions should exercise caution as flavonoids may exhibit estrogenic activity.